Digestive Diseases and Sciences

, Volume 53, Issue 10, pp 2714–2718

Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome

Authors

  • Dong Hyun Sinn
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
  • Ji Hyun Song
    • Healthcare System, Gangnam CenterSeoul National University Hospital
  • Hoi Jin Kim
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
  • Jun Haeng Lee
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
  • Hee Jung Son
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
  • Dong Kyung Chang
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
  • Young-Ho Kim
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
  • Jae J. Kim
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
  • Jong Chul Rhee
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
    • Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
    • Division of Gastroenterology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of Medicine
Original Paper

DOI: 10.1007/s10620-007-0196-4

Cite this article as:
Sinn, D.H., Song, J.H., Kim, H.J. et al. Dig Dis Sci (2008) 53: 2714. doi:10.1007/s10620-007-0196-4

Abstract

Probiotic bacteria exhibit a variety of properties, which are unique to a particular strain. Lactobacillus acidophilus-SDC 2012, 2013 are new strains isolated from Korean infants’ feces. The potential utility of Lactobacillus acidophilus-SDC 2012, 2013 in irritable bowel syndrome (IBS) was studied. Forty IBS patients were randomized into a placebo (n = 20) and probiotics group (n = 20). Four weeks of treatment with L. acidophilus-SDC 2012, 2013 was associated with a reduced score for abdominal pain or discomfort compared to the baseline (P = 0.011). The percent reduction in abdominal pain or discomfort exceeded the placebo scores by more than 20% (23.8 and 0.2% for probiotics and placebo, respectively, P = 0.003). There was a significant difference in the proportion of responders between the probiotics and placebo groups (P = 0.011). There was no drop out or adverse events for either group during the study period. Lactobacillus acidophilus-SDC 2012, 2013 appeared to have a beneficial effect in patients with IBS. Further studies are warranted.

Keywords

Probiotics Irritable bowel syndrome Lactobacillus acidophilus

Copyright information

© Springer Science+Business Media, LLC 2008